522 related articles for article (PubMed ID: 18440229)
1. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
[TBL] [Abstract][Full Text] [Related]
2. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.
Scarpelli R; Di Marco A; Ferrigno F; Laufer R; Marcucci I; Muraglia E; Ontoria JM; Rowley M; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6078-82. PubMed ID: 18952417
[TBL] [Abstract][Full Text] [Related]
3. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
5. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
6. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
7. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
[TBL] [Abstract][Full Text] [Related]
8. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
[TBL] [Abstract][Full Text] [Related]
9. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
11. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
12. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
[TBL] [Abstract][Full Text] [Related]
14. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
Jones P; Altamura S; De Francesco R; Gallinari P; Lahm A; Neddermann P; Rowley M; Serafini S; Steinkühler C
Bioorg Med Chem Lett; 2008 Mar; 18(6):1814-9. PubMed ID: 18308563
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
[TBL] [Abstract][Full Text] [Related]
16. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.
Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A
J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
18. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
[TBL] [Abstract][Full Text] [Related]
19. Design of novel histone deacetylase inhibitors.
Siliphaivanh P; Harrington P; Witter DJ; Otte K; Tempest P; Kattar S; Kral AM; Fleming JC; Deshmukh SV; Harsch A; Secrist PJ; Miller TA
Bioorg Med Chem Lett; 2007 Aug; 17(16):4619-24. PubMed ID: 17555962
[TBL] [Abstract][Full Text] [Related]
20. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors.
Wang DF; Wiest O; Helquist P; Lan-Hargest HY; Wiech NL
J Med Chem; 2004 Jun; 47(13):3409-17. PubMed ID: 15189037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
